[Articles] Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study

Journal content Created on 29 May 2026 The Lancet

• Details
• • All feed content
  • My feed content